Annemiek Broijl

4.8k total citations
50 papers, 710 citations indexed

About

Annemiek Broijl is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Annemiek Broijl has authored 50 papers receiving a total of 710 indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Hematology, 28 papers in Oncology and 20 papers in Molecular Biology. Recurrent topics in Annemiek Broijl's work include Multiple Myeloma Research and Treatments (43 papers), Protein Degradation and Inhibitors (15 papers) and Peptidase Inhibition and Analysis (10 papers). Annemiek Broijl is often cited by papers focused on Multiple Myeloma Research and Treatments (43 papers), Protein Degradation and Inhibitors (15 papers) and Peptidase Inhibition and Analysis (10 papers). Annemiek Broijl collaborates with scholars based in Netherlands, Italy and United States. Annemiek Broijl's co-authors include Pieter Sonneveld, Mark van Duin, Philippe Moreau, Bronno van der Holt, Remco M. Hoogenboezem, Tom Cupedo, Martin H. van Vliet, Erik H. van Beers, Jessica Vermeulen and Sonja Zweegman and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Annemiek Broijl

42 papers receiving 697 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Annemiek Broijl Netherlands	13	545	463	403	106	70	50	710
Jose Estevam United States	11	627 1.2×	566 1.2×	361 0.9×	45 0.4×	82 1.2×	16	754
Roberto Mina Italy	15	564 1.0×	483 1.0×	380 0.9×	37 0.3×	84 1.2×	51	679
Norbert Grząśko Poland	13	356 0.7×	285 0.6×	237 0.6×	40 0.4×	49 0.7×	39	488
Claudia E. Paba‐Prada United States	12	470 0.9×	462 1.0×	305 0.8×	55 0.5×	146 2.1×	27	658
Marina Martello Italy	10	352 0.6×	303 0.7×	218 0.5×	32 0.3×	48 0.7×	30	472
Marcy K. Vallone United States	8	466 0.9×	748 1.6×	335 0.8×	48 0.5×	83 1.2×	14	904
Paolo Ditonno Italy	9	258 0.5×	239 0.5×	201 0.5×	116 1.1×	25 0.4×	15	470
Mary McKenney United States	8	769 1.4×	655 1.4×	411 1.0×	36 0.3×	124 1.8×	11	871
Ying-Ming Jou United States	6	349 0.6×	353 0.8×	439 1.1×	60 0.6×	77 1.1×	8	631
Natalie D. Depcik‐Smith United States	4	318 0.6×	448 1.0×	271 0.7×	31 0.3×	88 1.3×	7	670

Countries citing papers authored by Annemiek Broijl

Since Specialization

Citations

This map shows the geographic impact of Annemiek Broijl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annemiek Broijl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annemiek Broijl more than expected).

Fields of papers citing papers by Annemiek Broijl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annemiek Broijl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annemiek Broijl. The network helps show where Annemiek Broijl may publish in the future.

Co-authorship network of co-authors of Annemiek Broijl

This figure shows the co-authorship network connecting the top 25 collaborators of Annemiek Broijl. A scholar is included among the top collaborators of Annemiek Broijl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annemiek Broijl. Annemiek Broijl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Landgren, Ola, Noa Biran, Elizabeth O’Donnell, et al.. (2025). Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma. HemaSphere. 9(7). e70178–e70178.

Rodríguez‐Otero, Paula, Philippe Moreau, Meletios Α. Dimopoulos, et al.. (2024). Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial.. Journal of Clinical Oncology. 42(16_suppl). 7502–7502. 9 indexed citations

Jong, Madelon M.E. de, Natalie Papazian, Remco M. Hoogenboezem, et al.. (2024). An IL-1β-driven neutrophil–stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma. Nature Immunology. 25(5). 820–833. 14 indexed citations

Raab, Marc S., Elena Zamagni, Salomon Manier, et al.. (2023). Difficult‐to‐treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results. SHILAP Revista de lepidopterología. 4(4). 1117–1131. 12 indexed citations

Sonneveld, Pieter, Sonja Zweegman, Michèle Cavo, et al.. (2022). Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma. HemaSphere. 6(10). e786–e786. 12 indexed citations

Bruinink, Davine Hofste op, Rowan Kuiper, Mark van Duin, et al.. (2022). Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile. Journal of Clinical Oncology. 40(27). 3132–3150. 16 indexed citations

Tahri, Sabrin, Madelon M.E. de Jong, Natalie Papazian, et al.. (2022). OAB-029: Single-cell transcriptomic analysis reveals reduction of cytotoxic NK cells in a subset of newly diagnosed multiple myeloma patients impacting outcome after daratumumab therapy. Clinical Lymphoma Myeloma & Leukemia. 22. S17–S18. 1 indexed citations

Frerichs, Kristine A., Monique C. Minnema, Mark‐David Levin, et al.. (2021). Efficacy and safety of daratumumab combined with all-transretinoic acid in relapsed/refractory multiple myeloma. Blood Advances. 5(23). 5128–5139. 27 indexed citations

Jong, Madelon M.E. de, Zoltán Kellermayer, Natalie Papazian, et al.. (2021). The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. Nature Immunology. 22(6). 769–780. 128 indexed citations

10.

Mutsaers, Pim, Hayri E. Balcıoğlu, Rowan Kuiper, et al.. (2021). V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma. Cancers. 13(9). 2219–2219. 12 indexed citations

11.

Brink, Mirian, Pieter Sonneveld, Monique C. Minnema, et al.. (2021). Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study. Blood Cancer Journal. 11(11). 178–178. 7 indexed citations

12.

Mateos, María‐Victoria, Katja Weisel, Valerio De Stefano, et al.. (2021). LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma (RRMM) receiving ≥3 prior lines of therapy.. Journal of Clinical Oncology. 39(15_suppl). 8041–8041. 4 indexed citations

13.

Broijl, Annemiek, et al.. (2021). VS38c and CD38-Multiepitope Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma. American Journal of Clinical Pathology. 157(4). 494–497. 10 indexed citations

14.

Touzeau, Cyrille, Philippe Moreau, Aurore Perrot, et al.. (2020). Daratumumab + bortezomib, thalidomide, and dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM): Baseline SLiM-CRAB based subgroup analysis of CASSIOPEIA.. Journal of Clinical Oncology. 38(15_suppl). 8538–8538. 5 indexed citations

15.

Wester, Ruth, Bronno van der Holt, Sonja Zweegman, et al.. (2019). Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial. Haematologica. 104(11). 2265–2273. 22 indexed citations

16.

Broijl, Annemiek, Monique C. Minnema, Sarah Lonergan, et al.. (2018). A phase II study of selinexor(KPT-330) combined with bortezomib and dexamethasone (SVD) for induction and consolidation for patients with progressive or refractory multiple myeloma: The selvedex trial. Pure Amsterdam UMC. 5 indexed citations

17.

Sonneveld, Pieter, et al.. (2018). Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects. Nature Communications. 9(1). 2943–2943. 19 indexed citations

18.

Minnema, Monique C., Kazem Nasserinejad, Bouke P. C. Hazenberg, et al.. (2017). HOVON 104; FINAL RESULTS FROM A MULTICENTER, PROSPECTIVE PHASE II STUDY OF BORTEZOMIB BASED INDUCTION TREATMENT FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH DE NOVO AL AMYLOIDOSIS. Data Archiving and Networked Services (DANS). 1 indexed citations

19.

Andel, Harmen van, Kinga A. Kocemba‐Pilarczyk, Clemens Mellink, et al.. (2016). Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease. Oncogene. 36(15). 2105–2115. 41 indexed citations

20.

Kuiper, Rowan, Mark van Duin, Martin H. van Vliet, et al.. (2015). Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. Blood. 126(17). 1996–2004. 77 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact